ストックスクリーナーアプリを入手
4.24
2.53%
-0.11
アフターアワーズ：
4.24
前日終値:
$4.35
開ける：
$4.23
24時間の取引高:
205.89K
Relative Volume:
0.44
時価総額：
$385.50M
収益：
$35.11M
当期純損益:
$-79.20M
株価収益率:
-0.9777
EPS:
-4.3367
ネットキャッシュフロー:
$-88.62M
1週間 パフォーマンス:
-1.62%
1か月 パフォーマンス:
+24.71%
6か月 パフォーマンス:
+21.84%
1年 パフォーマンス:
-38.01%
1日の値動き範囲:
$4.17
$4.435
1週間の範囲:
$3.89
$4.47
52週間の値動き範囲:
$1.35
$6.96
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.24 | 385.50M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - WHEC.com
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
If You Invested $1,000 in X4 Pharmaceuticals Inc (XFOR) - Stock Titan
X4 Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | | US98420X2027 - marketscreener.com
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen - MarketBeat
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PR Newswire
X4 Pharmaceuticals (NASDAQ: XFOR) seeks approval for equity plan and pay at 2026 meeting - Stock Titan
Q3 Earnings Forecast for XFOR Issued By Brookline Cap M - MarketBeat
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan
Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan
Children’s ibuprofen sold nationwide recalled by FDA - FOX8 WGHP
Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail
Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results - MarketBeat
Amphastar (AMPH) EVP Yakob has 1,033 shares withheld for RSU tax - Stock Titan
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10tv.com
EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028 - Stock Titan
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) cuts costs, raises cash to advance mavorixafor - Stock Titan
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Aug Sectors: Is X4 Pharmaceuticals Inc impacted by rising ratesPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):